Edwards Lifesciences Corp

EW

Edwards Lifesciences Corp

EW

Insider Sentiment (TTM):

Last Purchase:2024-05-06Last Sale:2026-06-30Shares Purchased (TTM):0Shares Sold (TTM):265,842.65

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:397,547,266Shares Outstanding:579,200,000Institutional Ownership Pct.:68.64%

Earnings Market Reaction:

Filing Date:2026-05-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Orthopedic, Prosthetic & Surgical Appliances & Supplies

ISRG STE ZBH ALGN MSA ESTA

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	2,446	2,938	2,686	3,273	3,141	3,045	3,676	1,645	1,225	1,132	1,410	1,043
Short Term Investments	1,226	1,288	1,156	789	758	931	770	345	473	501	454	467
Accounts Receivable Net Current	776	660	693	697	669	609	716	778	818	772	740	754
Other Receivables Net Current	197	253	200	206	83	118	96	56	59	57	-	-
Other Receivables	-	-	-	-	-	-	-	-	-	62	62	63
Inventory Net	1,119	1,126	1,141	1,142	1,114	1,087	1,104	1,025	1,207	904	1,032	980
Prepaid Expense Current	136	135	125	110	111	121	115	110	138	129	133	123
Other Assets Current	330	339	323	314	305	348	231	252	251	225	236	217
Assets Of Disposal Group Including Discontinued Op…	-	0	35	46	33	27	20	305	-	318	-	-
Assets Current	6,229	6,739	6,359	6,577	6,213	6,285	6,728	4,516	4,171	4,036	4,068	3,647
Long Term Investments	286	279	275	299	278	308	320	353	456	584	705	856
Property Plant And Equipment Net	1,823	1,812	1,743	1,727	1,698	1,686	1,676	1,640	1,768	1,591	1,681	1,662
Operating Lease Right Of Use Asset	99	103	97	99	97	98	104	93	98	84	91	85
Goodwill	1,820	1,769	1,769	1,777	1,779	1,777	1,605	1,151	1,253	1,145	1,297	1,300
Intangible Assets Net Excluding Goodwill	1,228	1,128	1,131	1,173	1,175	1,177	956	417	447	399	430	431
Deferred Income Tax Assets Net	1,098	1,138	1,100	1,082	1,028	992	888	833	777	749	652	611
Other Assets Noncurrent	739	730	785	743	743	722	684	790	768	463	447	412
Disposal Group Including Discontinued Operation As…	-	0	15	13	12	11	11	307	-	311	-	-
Assets	13,321	13,697	13,272	13,489	13,022	13,055	12,971	10,099	9,736	9,363	9,371	9,004
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	181	228	165	162	172	197	173	186	212	187	191	193
Operating Lease Liability Current	24	25	27	26	24	23	24	22	25	23	24	24
Liabilities Of Disposal Group Including Discontinu…	-	0	2	2	2	2	2	107	-	130	-	-
Liabilities Current	1,409	1,814	1,588	1,405	1,395	1,505	1,944	1,217	1,111	1,195	1,239	1,157
Long Term Debt Noncurrent	599	598	598	598	598	598	598	597	597	597	597	597
Operating Lease Liability Noncurrent	80	83	75	79	78	79	85	74	77	65	70	64
Business Combination Contingent Consideration Liab…	-	-	-	-	-	15	-	-	-	0	0	0
Liability For Uncertain Tax Positions Noncurrent	555	503	443	422	403	385	346	343	337	335	312	304
Taxes Payable Current And Noncurrent	-	-	-	-	-	1	1	1	80	81	81	81
Litigation Reserve Noncurrent	-	0	-	-	-	53	64	75	82	94	104	113
Other Liabilities Noncurrent	351	362	363	379	358	373	323	257	267	251	240	243
Liabilities Of Disposal Group Including Discontinu…	-	-	0	-	-	0	0	30	-	25	-	-
Liabilities	2,994	3,360	3,067	2,882	2,831	2,992	3,360	2,595	2,550	2,644	2,644	2,558
Stockholders Equity Inclu…
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	660	659	658	658	656	655	654	654	652	651	650	649
Additional Paid In Capital Common Stock	2,782	2,768	2,697	2,750	2,653	2,613	2,452	2,476	2,380	2,274	2,211	2,146
Retained Earnings Accumulated Deficit	14,621	14,241	14,149	13,858	13,525	13,167	12,781	9,711	9,344	8,992	8,623	8,238
Accumulated Other Comprehensive Income Loss Net Of…	-221	-238	-250	-264	-255	-245	-253	-220	-233	-243	-250	-256
Treasury Stock Common Value	-7,514	-7,092	-7,050	-6,456	-6,451	-6,192	-6,090	-5,183	-5,025	-5,025	-4,576	-4,401
Stockholders Equity	10,328	10,338	10,205	10,545	10,129	10,063	9,546	7,505	7,118	6,650	6,727	6,376
Minority Interest	-	0	0	61	63	65	66	67	69	69	70	71
Liabilities And Stockholders Equity	13,321	13,697	13,272	13,489	13,022	13,055	12,971	10,099	9,736	9,363	9,371	9,004
Allowance For Doubtful Accounts Receivable Current	16	15	13	13	13	12	13	14	14	8	8	8
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	50	50	50	50	50	50	50	50	50	50	50	50
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	1	1	1	1	1	1	1	1	1	1	1	1
Common Stock Shares Authorized	1,050	1,050	1,050	1,050	1,050	1,050	1,050	1,050	1,050	1,050	1,050	1,050
Common Stock Shares Issued	660	659	658	658	656	655	654	654	652	651	650	649
Shares Outstanding	577	581	581	588	586	589	590	602	602	601	607	608
Treasury Stock Common Shares	83	78	78	70	70	66	65	51	49	49	43	41

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	3.93%	9.11%	-0.69%	-	-	-	-	-	-	-	-	-
2025	4.40%	4.39%	6.78%	3.47%	-3.00%	-3.19%	4.62%	4.84%	0.99%	-1.08%	-2.89%	-2.42%
2024	2.36%	5.76%	0.64%	12.42%	6.00%	11.45%	8.52%	15.06%	4.93%	-1.62%	-0.13%	8.91%
2023	-	-	-	-8.55%	-12.59%	-15.48%	8.41%	24.62%	19.96%	5.76%	6.40%	-2.15%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	4.42	3.72	4.00	4.68	4.45	4.18	3.46	3.71	3.75	3.38	3.28	3.15
Quick Ratio	3.53	3.02	3.21	3.79	3.58	3.37	2.83	2.78	2.54	2.51	2.34	2.20
Working Capital	4.82B	4.93B	4.77B	5.17B	4.82B	4.78B	4.78B	3.30B	3.06B	2.84B	2.83B	2.49B
Leverage & Debt
Debt to Equity	0.29	0.32	0.30	0.27	0.28	0.30	0.35	0.35	0.36	0.39	0.39	0.40
Interest Coverage TTM	17.72	11.24	12.67	14.96	18.67	24.49	24.11	29.14	31.19	39.91	44.68	61.06
Debt Ratio	0.22	0.25	0.23	0.21	0.22	0.23	0.26	0.26	0.26	0.28	0.28	0.28
Efficiency & Turnover
Asset Turnover TTM	0.48	0.45	0.45	0.48	0.49	0.49	0.45	0.52	0.53	0.57	0.59	0.62
Days Sales Outstanding TTM	41.83	38.16	43.71	47.36	49.14	46.32	52.45	56.46	57.41	51.53	46.35	46.81
Receivables Turnover TTM	8.73	9.57	8.35	7.71	7.43	7.88	6.96	6.46	6.36	7.08	7.88	7.80
Per Share Metrics
Diluted EPS TTM	1.89	1.83	2.33	7.05	7.11	6.97	6.95	2.44	2.34	2.30	2.35	2.27
Free Cash Flow Per Share TTM	1.88	2.28	1.38	1.00	1.08	0.49	0.86	0.95	0.45	1.06	1.33	1.16
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	77.87%	78.01%	78.19%	78.87%	79.50%	79.46%	80.91%	80.74%	80.82%	80.47%	79.52%	79.75%
Operating Profit Margin TTM	21.37%	20.84%	24.23%	25.84%	25.80%	25.35%	26.79%	27.70%	26.01%	26.13%	27.41%	27.70%
Net Profit Margin TTM	17.42%	17.69%	23.19%	72.91%	75.69%	76.75%	82.12%	29.75%	28.95%	27.99%	26.73%	25.60%
Growth Metrics
Net Revenue Growth (1Y)	14.15%	11.55%	16.16%	14.75%	13.15%	8.57%	-5.27%	-8.63%	-11.28%	-6.92%	-0.32%	1.26%
Net Income Growth (1Y)	-73.74%	-74.28%	-67.19%	181.28%	195.85%	197.68%	191.02%	6.18%	-5.10%	-7.85%	-2.02%	-4.64%
EPS Growth (1Y)	-73.39%	-73.72%	-66.49%	188.51%	203.26%	202.16%	195.80%	7.03%	-4.17%	-5.98%	0.04%	-2.44%
Valuation Metrics
P/E TTM	42.25	46.44	33.32	11.08	10.18	10.60	9.47	37.74	40.69	32.99	29.42	41.25
P/B TTM	4.49	4.82	4.46	4.35	4.20	4.40	4.13	7.41	8.08	6.88	6.25	8.98
P/S TTM	7.36	8.22	7.73	8.08	7.70	8.13	7.78	11.23	11.78	9.23	7.87	10.56
Market Cap	46.38B	49.85B	45.47B	45.91B	42.54B	44.25B	39.41B	55.62B	57.49B	46.26B	42.05B	57.25B
Enterprise Value	44.53B	47.51B	43.38B	43.22B	39.99B	41.79B	36.32B	54.56B	56.86B	45.71B	41.24B	56.80B
Calculated Values
Free Cash Flow TTM	1.09B	1.34B	804.20M	587.90M	633.10M	289.90M	515.50M	571.80M	271.40M	642.80M	808.40M	702.20M
Net Debt	-1.85B	-2.34B	-2.10B	-2.69B	-2.55B	-2.46B	-3.09B	-1.06B	-631.80M	-551.00M	-817.10M	-450.80M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Insider Transactions

2026-06-30Sale

Owner: Lippis, Daniel J.

Title: CVP, TAVR

Shares: 619

Price/Share: $91.40

Value: $56,576.60

Shares Owned: 40,411

Relationship: Officer

Ownership: Direct

2026-06-17Sale

Owner: Zovighian, Bernard J

Title: CEO

Shares: 523

Price/Share: $87.92

Value: $45,982.16

Shares Owned: 11,517

Relationship: Director,Officer

Ownership: Indirect

2026-05-29Sale

Owner: Dahl, Andrew M.

Title: SVP, Corporate Controller

Shares: 568

Price/Share: $86.08

Value: $48,852.98

Shares Owned: 15,334

Relationship: Officer

Ownership: Direct

2026-05-27Sale

Owner: Bobo, Donald E Jr

Title: CVP,Strategy/Corp Development

Shares: 23,145

Price/Share: $86.42

Value: $2,000,190.90

Shares Owned: 98,611

Relationship: Officer

Ownership: Indirect

2026-05-22Sale

Owner: Chopra, Daveen

Title: CVP, TMTT & Surgical

Shares: 1,500

Price/Share: $84.60

Value: $126,900.00

Shares Owned: 44,324

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-30	Lippis, Daniel J.	Officer	CVP, TAVR	Direct	Sale	619	91.40	$56,576.60	40,411	4
2026-06-17	Zovighian, Bernard J	Director,Officer	CEO	Indirect	Sale	523	87.92	$45,982.16	11,517	4
2026-05-29	Dahl, Andrew M.	Officer	SVP, Corporate Controller	Direct	Sale	568	86.08	$48,852.98	15,334	4
2026-05-27	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Indirect	Sale	23,145	86.42	$2,000,190.90	98,611	4
2026-05-22	Chopra, Daveen	Officer	CVP, TMTT & Surgical	Direct	Sale	1,500	84.60	$126,900.00	44,324	4
2026-05-18	Lippis, Daniel J.	Officer	CVP, TAVR	Direct	Sale	620	81.14	$50,306.80	40,411	4
2026-05-15	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	9,968	82.07	$818,073.76	22,798	4
2026-05-12	Zovighian, Bernard J	Director,Officer	CEO	Indirect	Sale	36,351	78.16	$2,841,194.16	12,040	4
2026-05-11	Markowitz, Wayne	Officer	CVP, JAPAC	Direct	Sale	593	79.73	$47,279.89	21,680	4
2026-05-04	Lippis, Daniel J.	Officer	CVP, TAVR	Direct	Sale	1,019	83.98	$85,575.62	33,682	4
2026-04-09	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	13,000	80.15	$1,041,950.00	39,699	4
2026-04-06	Lippis, Daniel J.	Officer	CVP, TAVR	Direct	Sale	1,019	80.98	$82,518.62	33,934	4
2026-04-02	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	22,680	80.32	$1,821,657.60	21,266	4
2026-03-11	Lippis, Daniel J.	Officer	CVP, TAVR	Direct	Sale	1,019	85.38	$87,002.22	33,934	4
2026-03-11	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	13,000	84.84	$1,102,920.00	39,699	4
2026-03-02	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	11,340	85.93	$974,446.20	21,266	4
2026-02-25	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	24,000	83.84	$2,012,160.00	21,266	4
2026-02-12	Zovighian, Bernard J	Director,Officer	CEO	Direct	Sale	22,430	76.87	$1,724,194.10	83,896	4
2026-01-09	Lippis, Daniel J.	Officer	CVP, TAVR	Direct	Sale	1,019	85.70	$87,328.30	22,002	4
2026-01-06	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	11,340	85.30	$967,302.00	31,870	4
2025-12-12	Stone, Heisz Leslie	Director	-	Direct	Sale	2,615	83.41	$218,117.15	30,948	4
2025-12-12	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	11,386	83.76	$953,701.41	38,970	4
2025-12-12	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	1,019	84.03	$85,626.57	22,002	4
2025-12-11	Chopra, Daveen	Officer	CVP, TMTT & Surgical	Direct	Sale	2,000	84.38	$168,760.00	32,201	4
2025-12-10	Zovighian, Bernard J	Director,Officer	CEO	Indirect	Sale	3,863	83.45	$322,367.35	8,597	4
2025-12-10	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	11,340	83.83	$950,632.20	50,356	4
2025-12-09	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	7,700	84.47	$650,419.00	39,898	4
2025-12-08	Markowitz, Wayne	Officer	CVP, JAPAC	Direct	Sale	583	86.01	$50,143.83	17,563	4
2025-11-10	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	13,000	83.16	$1,081,080.00	39,898	4
2025-11-10	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	1,020	82.55	$84,201.00	22,002	4
2025-08-25	Chopra, Daveen	Officer	CVP, TMTT	Direct	Sale	2,500	81.95	$204,875.00	30,996	4
2025-08-18	Wood, Larry L	Officer	Global President TAVR & Surg	Direct	Sale	8,950	78.06	$698,637.00	206,900	4
2025-07-28	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	4,114	79.46	$326,898.44	22,002	4
2025-06-16	Wood, Larry L	Officer	Global President TAVR & Surg	Direct	Sale	8,950	75.23	$673,308.50	206,900	4
2025-06-03	Zovighian, Bernard J	Director,Officer	CEO	Indirect	Sale	967	77.32	$74,768.44	8,597	4
2025-06-02	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	2,570	77.40	$198,918.00	50,356	4
2025-05-22	Chopra, Daveen	Officer	CVP, TMTT	Direct	Sale	1,500	75.08	$112,620.00	33,496	4
2025-05-09	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	11,250	74.40	$837,000.00	41,098	4
2025-05-09	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	330	74.42	$24,558.60	26,616	4
2025-05-07	Markowitz, Wayne	Officer	GM & SVP, Surgical	Direct	Sale	268	75.08	$20,121.44	9,299	4
2025-05-05	Zovighian, Bernard J	Director,Officer	CEO	Direct	Sale	5,980	74.91	$447,961.80	58,284	4
2025-04-14	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	9,500	69.81	$663,195.00	47,206	4
2025-04-08	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	300	70.61	$21,183.00	22,863	4
2025-03-26	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	11,250	70.87	$797,287.50	30,387	4
2025-03-13	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	9,500	67.96	$645,620.00	46,936	4
2025-03-10	Zovighian, Bernard J	Director,Officer	CEO	Direct	Sale	6,164	69.51	$428,459.64	59,083	4
2025-03-10	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	400	69.48	$27,792.00	22,588	4
2025-02-28	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	11,250	70.95	$798,187.50	30,387	4
2025-02-14	Loranger, Steven R	Director	-	Direct	Sale	5,739	76.42	$438,574.38	60,372	4
2025-02-13	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	11,250	75.76	$852,300.00	30,561	4
2025-02-13	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	500	76.34	$38,170.00	23,189	4
2025-02-13	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	6,500	76.00	$494,000.00	46,936	4
2025-02-13	Stone, Heisz Leslie	Director	-	Direct	Sale	5,739	75.86	$435,360.54	30,035	4
2025-01-16	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	500	68.76	$34,380.00	23,189	4
2025-01-16	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	5,000	68.75	$343,750.00	46,936	4
2024-12-16	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	2,500	74.08	$185,200.00	23,189	4
2024-12-09	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	11,250	71.68	$806,400.00	30,561	4
2024-12-09	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	5,000	71.75	$358,750.00	46,936	4
2024-12-06	Chopra, Daveen	Officer	CVP, TMTT	Direct	Sale	1,750	73.27	$128,222.50	27,583	4
2024-12-06	Markowitz, Wayne	Officer	GM & SVP, Surgical	Direct	Sale	583	73.27	$42,716.41	9,494	4
2024-11-13	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	5,000	65.57	$327,850.00	46,936	4
2024-11-05	Wood, Larry L	Officer	Global President TAVR & Surg	Direct	Sale	25,000	65.91	$1,647,750.00	198,526	4
2024-10-15	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	5,000	69.51	$347,550.00	46,936	4
2024-09-11	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	5,000	66.77	$333,850.00	46,936	4
2024-08-20	Chopra, Daveen	Officer	CVP, TMTT	Direct	Sale	1,250	69.95	$87,437.50	29,333	4
2024-08-14	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	5,000	66.08	$330,400.00	46,936	4
2024-07-11	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	500	94.18	$47,090.00	23,189	4
2024-07-10	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	5,000	93.29	$466,450.00	46,936	4
2024-06-20	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	5,625	87.79	$493,818.75	30,561	4
2024-06-20	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	535	90.00	$48,150.00	23,513	4
2024-06-12	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	5,000	87.54	$437,700.00	46,936	4
2024-05-30	Zovighian, Bernard J	Director,Officer	CEO	Direct	Sale	8,617	87.68	$755,538.56	68,218	4
2024-05-21	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	5,625	90.45	$508,781.25	30,561	4
2024-05-10	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	5,000	87.81	$439,050.00	47,750	4
2024-05-07	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	857	85.60	$73,359.20	23,890	4
2024-05-06	Zovighian, Bernard J	Director,Officer	CEO	Indirect	Purchase	580	85.74	$49,751.49	3,268	4
2024-05-02	Mussallem, Michael A	Director	-	Direct	Sale	29,350	84.80	$2,488,880.00	4,486	4
2024-05-01	Lemercier, Jean-Luc M	Officer	CVP, EMEACLA and JAPAC	Direct	Sale	14,400	84.47	$1,216,368.00	173,849	4
2024-04-30	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	7,250	86.07	$624,007.50	19,074	4
2024-04-09	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	857	92.34	$79,135.38	17,488	4
2024-04-08	Lemercier, Jean-Luc M	Officer	CVP, EMEACLA	Direct	Sale	14,400	92.48	$1,331,712.00	173,849	4
2024-04-08	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	12,500	92.50	$1,156,250.00	39,768	4
2024-04-04	Mussallem, Michael A	Director	-	Direct	Sale	29,350	93.04	$2,730,724.00	4,486	4
2024-04-01	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	7,255	95.16	$690,385.80	19,074	4
2024-03-13	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	14,500	91.01	$1,319,645.00	39,503	4
2024-03-11	Lemercier, Jean-Luc M	Officer	CVP, EMEACLA and JAPAC	Direct	Sale	14,400	91.68	$1,320,192.00	173,584	4
2024-03-07	Lippis, Daniel J.	Officer	CVP, JAPAC	Direct	Sale	1,715	90.98	$156,030.70	17,213	4
2024-03-04	Mussallem, Michael A	Director	-	Direct	Sale	29,350	86.63	$2,542,590.50	4,486	4
2024-02-29	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	7,255	85.59	$620,955.45	19,074	4
2024-02-23	Gallahue, Kieran	Director	-	Indirect	Sale	3,058	87.61	$267,911.38	67,219	4
2024-02-21	Chopra, Daveen	Officer	CVP, TMTT	Direct	Sale	8,200	86.71	$711,022.00	22,750	4
2024-02-15	Szyman, Catherine M.	Officer	CVP, Critical Care	Direct	Sale	27,000	85.62	$2,311,740.00	34,814	4
2024-02-13	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	11,000	86.08	$946,880.00	39,503	4
2024-02-12	Sellers, Robert W.A.	Officer	SVP, Corporate Controller	Direct	Sale	12,210	87.00	$1,062,270.00	13,087	4
2024-02-08	Stone, Heisz Leslie	Director	-	Direct	Sale	7,056	86.45	$609,991.20	26,980	4
2024-02-05	Mussallem, Michael A	Director	-	Direct	Sale	29,350	88.06	$2,584,561.00	4,486	4
2024-02-01	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	7,255	78.29	$567,993.95	19,248	4
2024-01-12	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	10,000	75.67	$756,700.00	39,503	4
2024-01-05	Mussallem, Michael A	Director	-	Direct	Sale	29,350	73.20	$2,148,420.00	4,486	4
2023-12-29	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	14,510	76.55	$1,110,740.50	19,248	4
2023-12-15	Chopra, Daveen	Officer	CVP, TMTT	Direct	Sale	7,000	78.25	$547,750.00	23,950	4
2023-12-13	Mussallem, Michael A	Director	-	Direct	Sale	29,350	74.56	$2,188,336.00	4,486	4
2023-12-13	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	8,000	71.86	$574,880.00	39,503	4
2023-12-13	Wood, Larry L	Officer	Global President TAVR & Surg	Direct	Sale	8,658	71.86	$622,163.88	213,794	4
2023-12-06	Chopra, Daveen	Officer	CVP, TMTT	Direct	Sale	3,500	70.00	$245,000.00	23,950	4
2023-11-13	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	6,000	65.19	$391,140.00	39,503	4
2023-11-13	Wood, Larry L	Officer	Global President TAVR & Surg	Direct	Sale	8,660	65.51	$567,316.60	213,794	4
2023-11-03	Mussallem, Michael A	Director	-	Direct	Sale	29,350	67.18	$1,971,733.00	4,486	4
2023-10-31	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	7,255	62.66	$454,598.30	19,248	4
2023-10-13	Wood, Larry L	Officer	Global President TAVR & Surg	Direct	Sale	8,660	69.94	$605,680.40	213,794	4
2023-10-13	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	5,000	69.91	$349,550.00	39,503	4
2023-10-10	Szyman, Catherine M.	Officer	CVP, Critical Care	Direct	Sale	5,000	72.68	$363,400.00	34,814	4
2023-10-03	Chopra, Daveen	Officer	CVP, TMTT	Direct	Sale	8,500	70.00	$595,000.00	23,950	4
2023-10-02	Mussallem, Michael A	Director	-	Direct	Sale	29,350	68.84	$2,020,454.00	4,486	4
2023-09-29	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	7,255	69.54	$504,512.70	19,248	4
2023-09-14	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	4,500	73.71	$331,695.00	39,503	4
2023-09-14	Wood, Larry L	Officer	Global President TAVR & Surg	Direct	Sale	8,660	73.63	$637,635.80	213,794	4
2023-09-08	Szyman, Catherine M.	Officer	CVP, Critical Care	Direct	Sale	5,000	76.00	$380,000.00	34,814	4
2023-09-06	Chopra, Daveen	Officer	CVP, TMTT	Direct	Sale	8,500	76.07	$646,595.00	23,950	4
2023-09-05	Mussallem, Michael A	Director	-	Direct	Sale	29,350	75.86	$2,226,491.00	4,486	4
2023-08-31	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	7,255	77.79	$564,366.45	19,248	4
2023-08-29	Chopra, Daveen	Officer	CVP, TMTT	Direct	Sale	1,500	76.69	$115,035.00	23,950	4
2023-08-14	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	4,500	79.30	$356,850.00	39,503	4
2023-08-14	Wood, Larry L	Officer	Global President TAVR & Surg	Direct	Sale	6,421	79.30	$509,185.30	213,794	4
2023-08-10	Stone, Heisz Leslie	Director	-	Direct	Sale	3,303	78.87	$260,507.61	26,980	4
2023-08-09	Szyman, Catherine M.	Officer	CVP, Critical Care	Direct	Sale	5,000	78.64	$393,200.00	34,814	4
2023-08-07	Mussallem, Michael A	Director	-	Direct	Sale	29,350	80.20	$2,353,870.00	54,252	4
2023-07-31	Ullem, Scott B.	Officer	CVP, Chief Financial Officer	Direct	Sale	7,255	84.35	$611,959.25	19,248	4
2023-07-14	Bobo, Donald E Jr	Officer	CVP,Strategy/Corp Development	Direct	Sale	3,500	92.94	$325,290.00	39,503	4
2023-07-14	Wood, Larry L	Officer	Global President TAVR & Surg	Direct	Sale	8,660	92.94	$804,860.40	213,794	4
2023-07-10	Szyman, Catherine M.	Officer	CVP, Critical Care	Direct	Sale	5,000	90.52	$452,600.00	34,814	4
2023-07-05	Mussallem, Michael A	Director	-	Direct	Sale	29,350	90.92	$2,668,502.00	54,252	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Institutional Ownership

No data available for chart

2026-03-31

68.64%

Inst. Shares: 397,547,266

Shares Outstanding: 579,200,000

2025-12-31

83.59%

Inst. Shares: 488,820,952

Shares Outstanding: 584,800,000

2025-09-30

81.96%

Inst. Shares: 479,226,688

Shares Outstanding: 584,700,000

2025-06-30

83.24%

Inst. Shares: 488,646,408

Shares Outstanding: 587,000,000

2025-03-31

82.51%

Inst. Shares: 484,234,735

Shares Outstanding: 586,900,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	397,547,266	579,200,000	68.64%
2025-12-31	488,820,952	584,800,000	83.59%
2025-09-30	479,226,688	584,700,000	81.96%
2025-06-30	488,646,408	587,000,000	83.24%
2025-03-31	484,234,735	586,900,000	82.51%
2024-12-31	483,844,745	597,700,000	80.95%
2024-09-30	451,131,095	597,200,000	75.54%
2024-06-30	464,560,113	602,100,000	77.16%
2024-03-31	447,420,689	601,600,000	74.37%
2023-12-31	450,212,618	606,700,000	74.21%
2023-09-30	451,465,451	607,000,000	74.38%
2023-06-30	448,170,893	606,900,000	73.85%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Edwards Lifesciences Corp (EW) — SEC Financial Statements & Analysis

Edwards Lifesciences Corp (EW) is a orthopedic, prosthetic & surgical appliances & supplies company, incorporated in DE. Edwards Lifesciences Corp trades on EW: NYSE as: EW. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Edwards Lifesciences Corp reported a 14.15% year-over-year revenue growth, a Gross Profit Margin of 77.87% (TTM), a Debt-to-Equity ratio of 0.29x, a Price-to-Sales (P/S) ratio of 7.36x (TTM), a Price-to-Book (P/B) ratio of 4.49 (TTM), at a market cap of $46.38B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 14.15%
Gross Profit Margin TTM: 77.87%
Debt To Equity: 0.29x
P/S TTM: 7.36x
P/B TTM: 4.49
Market Cap: $46.38B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Edwards Lifesciences Corp in?

Edwards Lifesciences Corp (EW) operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry.

What is EW's market cap?

Edwards Lifesciences Corp (EW) has a market capitalization of $46.38B as of 2026-03-31.

What is EW's P/E ratio?

Edwards Lifesciences Corp (EW)'s trailing twelve month P/E ratio is 42.25x as of 2026-03-31.

What exchange does EW trade on?

Edwards Lifesciences Corp (EW) trades on the EW: NYSE.

Where is Edwards Lifesciences Corp incorporated?

Edwards Lifesciences Corp is incorporated in DE.

Edwards Lifesciences Corp (EW) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.